Yuhan Corporation acquires approval of clinical trial for cancer immunotherapy for first time in Korea
ImmuneOncia(CEO Kwang-Ho Jung), a subsidiary of Yuhan Corporation, announced that the company has acquired approval of the Phase I clinical trial plan for IMC-011, a cancer immunotherapy, from the Ministry of Food and Drug Safety on 1 February. It was the first one which acquired approval as a Ko...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
